Akèy › Kansè Utèrin › Oklahoma
Etid klinik pou Kansè Utèrin nan Oklahoma
4 etid pou Kansè Utèrin ap chèche patisipan nan sit nan Oklahoma.
Vil nan Oklahoma
Tèks ofisyèl etid la (Anglè)
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
- Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa
Ap rekriteFaz 4
Laj 18 ak plis · Fanm · Mizajou Sep 25, 2026 · NCT06952660DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT06989112Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Oklahoma - Health Sciences Center, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Dec 11, 2025 · NCT06795009Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.